Know Cancer

or
forgot password

The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function


N/A
18 Years
N/A
Not Enrolling
Both
Colorectal Cancer, Lung Cancer, Breast Cancer, Glioblastoma

Thank you

Trial Information

The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function


Inclusion Criteria:



- Patients with colorectal cancer, lung cancer, breast cancer, and glioblastoma
patients that have been treated with Bevacizumab for at least 1 month

- Adults (18 years of age or older)

Exclusion Criteria:

- Patients who are taking medications known to affect serum prolactin levels

- Patients who are pregnant

- Patients who have pituitary disease

- Minors (Under the age of 18)

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Cross-Sectional

Outcome Measure:

To determine whether the drug, Bevacizumab (a monoclonal anti VEGF-A antibody), which is approved to treat patients with metastatic colon cancer induces hyperprolactinemia (increased prolactin secretion) in humans with intact pituitary function.

Outcome Description:

Patients will have their blood drawn before their first Bevacizumab infusion and then again 6 weeks later.

Outcome Time Frame:

6 weeks

Safety Issue:

No

Principal Investigator

Shlomo Melmed, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Cedars-Sinai Medical Center

Authority:

United States: Institutional Review Board

Study ID:

Pro00019830

NCT ID:

NCT00973557

Start Date:

September 2009

Completion Date:

January 2012

Related Keywords:

  • Colorectal Cancer
  • Lung Cancer
  • Breast Cancer
  • Glioblastoma
  • bevacizumab
  • Breast Neoplasms
  • Colorectal Neoplasms
  • Glioblastoma
  • Lung Neoplasms

Name

Location
Cedars-Sinai Medical Center Los Angeles, California  90048